Marbodin (Memantine)

Memantine blocks the NMDA receptor’s ion channel in a non‑competitive manner, reducing calcium influx caused by overstimulation with glutamate. This limits excitotoxic damage to neurons, a key factor in the progression of Alzheimer’s disease.

The specific dose of Marbodin is determined by the prescribing clinician based on the patient’s condition, age, renal function and other factors. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety of memantine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Marbodin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. While both improve symptoms, memantine is typically used in moderate to severe stages and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Marbodin should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability.

Marbodin is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless instructed otherwise.

Serious risks include the potential for seizures, severe allergic reactions, hallucinations, and cardiac arrhythmias. Patients should be monitored for these events, and any sudden changes in neurological or cardiac status should prompt immediate medical evaluation.

Marbodin is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists.